Why BioCryst Pharmaceuticals Stock Caught Fire Today

Why BioCryst Pharmaceuticals Stock Caught Fire Today


The catalyst behind this surge higher is the news that the company's experimental hereditary angioedema drug candidate, BCX7353, continued to post impressive results in a mid-stage dose ranging study based on a second interim analysis. Specifically, the company reported that the intent-to-treat population exhibited significant reductions in HAE attacks for both the 125 mg and the 350 mg doses, compared to placebo.



from Biotech News